It is well known that the renin-angiotensin-aldosterone system (RAAS) has negative influence on blood pressure, heart failure and overall cardiovascular risk. Now, an increasing body of evidence show that the RAAS has a negative role in cell proliferation, angiogenesis, and tumor progression. This meta-analysis of randomized controlled trials helps place the RAAS’ influence on tumor progression in proper perspective.

***(Note: Only registered users can read and contribute to the discussion of this topic). Click here to register.


Time Required (estimated): 30 minutes
Title: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
Citation: Lancet Oncology 2010, Volume 11, pp. 627-36
Date Created: 2010
Revisions: None Indicated
Disclaimers: Pfizer, Astra-Zeneca, Ranbaxy, among other sponsors (see page 635)
Resource Type: Text
Other: Presented by Dr. Reginald Obi at ECU Nephrology Journal Club on 10/19/10


Recommend to a Colleague/Friend
Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.
Click here for the full-text article if you are a registered ECU/PCMH member and are outside the ECU/PCMH campus

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription